
Walker Chandiook & Co LLP

21st Floor, DLF Square
Jacaranda Marg, DLF Phase II,
Gurugram - 122002
Haryana, India
T +91 124 462 8099
F +91 124 462 8001

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ("the Statement") of Jubilant Ingrevia Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate (refer Annexure 1 for the list of subsidiaries and associate included in the Statement) for the quarter ended 30 September 2021 and the consolidated year to date results for the period 1 April 2021 to 30 September 2021, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the consolidated figures for the corresponding quarter and year-to-date period ended 30 September 2020, as reported in the Statement, have been approved by the Holding Company's Board of Directors but have not been subjected to audit or review. Attention is drawn to the fact that the cash flow figures for the corresponding half year ended 30 September 2020 have been approved by the Holding Company's Board of Directors but have not been subjected to audit or review.
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.



Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of review report of other auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement includes the Group's share of net loss after tax of ₹ 2 lakhs and ₹ 3 lakhs and total comprehensive loss of ₹ 2 lakhs and ₹ 3 lakhs, for the quarter and year-to-date period ended on 30 September 2021, respectively, as considered in the accompanying Statement, in respect of an associate, whose interim financial information have not been reviewed by us. This interim financial information has been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of this associate is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the report of the other auditor.

6. We draw attention to Note 5 of the accompanying Statement, which represents supplementary information relating to the operations of the life science ingredients business for the corresponding periods i.e., quarter and year-to-date period ended 30 September 2020 and for the period from 1 April 2020 to 31 January 2021, which has been prepared by the management of the Holding Company and has not been subjected to an audit or a review by us. Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Ashish Gupta

Partner

Membership No. 504662

eSigned using Cloud DSC
(Leegality.com - 3YzN3f2)
Ashish Gupta

Date: Tue Oct 19 13:53:26 IST
2021



UDIN: 21504662AAAAHZ3406

Place: New Delhi

Date: 19 October 2021

Annexure 1 to the Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

Annexure 1

List of entities included in the Statement

S. No.	Name	Relationship with the Holding Company
1	Jubilant Infrastructure Limited	Subsidiary
2	Jubilant Crop Protection Limited	Subsidiary (with effect from 2 June 2021)
3	Jubilant Life Sciences (USA) Inc.	Subsidiary
4	Jubilant Life Sciences NV	Subsidiary
5	Jubilant Life Sciences International Pte. Limited	Subsidiary
6	Jubilant Life Sciences (Shanghai) Limited	Subsidiary
7	Jubilant Ingrevia Employee Welfare Trust	Subsidiary
8	Mister Veg Foods Private Limited	Associate



Jubilant Ingrevia Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubil.com, Tel: +91-5924-267437

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30 September 2021

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30 September	30 June	30 September	30 September	30 September	31 March
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2021	2021	2020	2021	2020	2021
1	Revenue from operations						
	a) Sales/Income from operations	121707	113848	-	235555	-	67897
	b) Other operating income	550	608	-	1158	-	516
	Total revenue from operations	122257	114456	-	236713	-	68413
2	Other income	696	598	-	1294	-	260
3	Total income (1+2)	122953	115054	-	238007	-	68673
4	Expenses						
	a) Cost of materials consumed	73705	60822	-	134527	-	36348
	b) Purchases of stock-in-trade	4238	3387	-	7625	-	1598
	c) Changes in inventories of finished goods, stock-in-trade and work-in progress	(5720)	(6266)	-	(11986)	-	(951)
	d) Employee benefits expense	7587	8100	-	15687	-	4902
	e) Finance costs	716	1281	-	1997	-	733
	f) Depreciation and amortisation expense	3059	3162	-	6221	-	2206
	g) Other expenses:						
	- Power and fuel expense	10659	8353	-	19012	-	5171
	- Others	12256	11909	-	24165	-	9633
	Total expenses	106500	90748	-	197248	-	59640
5	Profit before share of loss of an associate and exceptional items (3-4)	16453	24306	-	40759	-	9033
6	Share of loss of an associate	(2)	(1)	-	(3)	-	-
7	Profit before exceptional items and tax (5+6)	16451	24305	-	40756	-	9033
8	Exceptional items	-	-	-	-	-	1294
9	Profit before tax (7-8)	16451	24305	-	40756	-	7739
10	Tax expense						
	- Current tax	2900	4370	-	7270	-	1336
	- Deferred tax charge	2472	3109	-	5581	-	967
11	Net profit for the period (9-10)	11079	16826	-	27905	-	5436
12	Other comprehensive income (OCI)						
	i) a) Items that will not be reclassified to profit or loss	8487	236	-	8723	-	486
	b) Income tax relating to items that will not be reclassified to profit or loss	101	(11)	-	90	-	12
	ii) a) Items that will be reclassified to profit or loss	(44)	72	-	28	-	-
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total comprehensive income for the period (11+12)	19623	17123	-	36746	-	5934
	Net profit attributable to:						
	Owners of the Company	11079	16826	-	27905	-	5436
	Non-controlling interests	-	-	-	-	-	-
	Other comprehensive income attributable to:						
	Owners of the Company	8544	297	-	8841	-	498
	Non-controlling interests	-	-	-	-	-	-
	Total comprehensive income attributable to:						
	Owners of the Company	19623	17123	-	36746	-	5934
	Non-controlling interests	-	-	-	-	-	-
14	Earnings per share of ₹ 1 each (not annualised)						
	Basic (₹)	6.97	10.58	-	17.55	-	20.78
	Diluted (₹)	6.97	10.58	-	17.55	-	20.78
15	Paid-up equity share capital (face value per share ₹ 1)	1590	1590	5	1590	5	1593
16	Reserves excluding revaluation reserves (other equity)				225123	(17)	190701
	See accompanying notes to the Consolidated Unaudited Financial Results						



Jubilant Ingrevia Limited

Statement of Consolidated Unaudited Assets and Liabilities

(₹ in Lakhs)

Sr. No.	Particulars	As at	As at
		30 September	31 March
		(Unaudited)	(Audited)
		2021	2021
A	ASSETS		
1.	Non-current assets		
	Property, plant and equipment	173231	174478
	Capital work-in-progress	9262	6317
	Intangible assets	1012	1110
	Intangible assets under development	321	191
	Right-of-use assets	4986	4921
	Investments accounted for using the equity method	213	216
	Financial assets:		
	Investments	345	4808
	Loans	49	53
	Other financial assets	360	310
	Deferred tax assets (net)	1478	1239
	Income-tax assets (net)	508	384
	Other non-current assets	1691	1466
	Total non-current assets	193456	195493
2.	Current assets		
	Inventories	76551	60910
	Financial assets:		
	Trade receivables	59344	47103
	Cash and cash equivalents	5064	7334
	Other bank balances	1966	4326
	Loans	52	51
	Other financial assets	7614	6780
	Income tax assets (net)	3	-
	Other current assets	17707	15855
	Total current assets	168301	142359
	Total assets	361757	337852
B	EQUITY AND LIABILITIES		
1.	Equity		
	Equity share capital	1590	1593
	Other equity	225123	190701
	Total equity attributable to equity holders	226713	192294
2.	Liabilities		
	Non-current liabilities		
	Financial liabilities:		
	Borrowings	18419	45584
	Lease liabilities	801	808
	Provisions	7029	6944
	Deferred tax liabilities (net)	8519	2789
	Total non-current liabilities	34768	56125
	Current liabilities		
	Financial liabilities:		
	Borrowings	7850	8966
	Lease liabilities	242	209
	Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	1119	1372
	Total outstanding dues of creditors other than micro enterprises and small enterprises	77300	68034
	Other financial liabilities	4310	6793
	Other current liabilities	3212	2335
	Provisions	1690	1219
	Current tax liabilities (net)	4553	505
	Total current liabilities	100276	89433
	Total equity and liabilities	361757	337852



Jubilant Ingrevia Limited
Note 1: Statement of Consolidated Unaudited Cash Flows

(₹ in lakhs)

Particulars	Half Year Ended	
	30 September	30 September
	(Unaudited)	(Unaudited)
	2021	2020
A. Cash flows from operating activities		
Profit before tax	40756	-
Adjustments:		
Depreciation and amortisation expense	6221	-
Loss on sale/ disposal/ discard of property, plant and equipment (net)	527	-
Finance costs	1997	-
Share-based payment expense	55	-
Unrealised foreign exchange loss (net)	268	-
Interest income	(71)	-
Share of loss of an associate	3	-
	9000	-
Operating cash flows before working capital changes	49756	-
Increase in trade receivables, loans, other financial assets and other assets	(15320)	-
Increase in inventories	(15676)	-
Increase in trade payables, other financial liabilities, other liabilities and provisions	8724	-
Cash generated from operations	27484	-
Income tax paid (net of refund)	(3526)	-
Net cash generated from operating activities	23958	-
B. Cash flows from investing activities		
Purchase of property, plant and equipment, other intangible assets (including capital work-in-progress and intangible assets under development)	(9495)	-
Proceeds from sale of property, plant and equipment	138	-
Proceeds from sale of investments	13421	-
Movement in other bank balances	2311	-
Interest received	76	-
Net cash generated from investing activities	6451	-
C. Cash flows from financing activities		
Acquisition of shares by employee welfare trust	(1826)	-
Repayment of long-term borrowings	(32969)	-
Payment of principal balances of lease liabilities	(158)	-
Proceeds from short-term borrowings (net)	4500	-
Dividend paid	(551)	-
Finance costs paid (including interest on lease liabilities)	(2076)	-
Net cash used in financing activities	(33080)	-
D. Effect of exchange rate changes	401	-
Net decrease in cash and cash equivalents (A+B+C+D)	(2270)	-
Add: cash and cash equivalents at the beginning of the period	7334	5
Cash and cash equivalents at the end of the period	5064	5



Jubilant Ingrevia Limited

Note2: Consolidated Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Half Year Ended 30 September 2021

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30 September	30 June	30 September	30 September	30 September	31 March
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2021	2021	2020	2021	2020	2021
1	Segment revenue						
	a. Speciality Chemicals	39170	38756	-	77926	-	25957
	b. Nutrition & Health Solutions	17880	16708	-	34588	-	12800
	c. Life Science Chemicals	77899	71017	-	148916	-	35946
	Total	134949	126481		261430		74703
	Less : Inter segment revenue	12692	12025	-	24717	-	6290
	Total revenue from operations	122257	114456		236713		68413
	a. Speciality Chemicals	29509	30465	-	59974	-	20827
	b. Nutrition & Health Solutions	17880	16708	-	34588	-	12800
	c. Life Science Chemicals	74868	67283	-	142151	-	34786
	Total	122257	114456		236713		68413
2	Segment results (profit before tax, exceptional items and interest from each segment)						
	a. Speciality Chemicals	5472	6702	-	12174	-	3477
	b. Nutrition & Health Solutions	3156	2319	-	5475	-	1955
	c. Life Science Chemicals	9226	17308	-	26534	-	4560
	Total	17854	26329		44183		9992
	Less: i. Interest (finance costs)	716	1281	-	1997	-	733
	ii. Exceptional items and un-allocable expenditure (net of un-allocable income)	687	743	-	1430	-	1520
	Profit before tax	16451	24305		40756		7739
3	Segment assets						
	a. Speciality Chemicals	164397	168740	-	164397	-	155357
	b. Nutrition & Health Solutions	46883	43126	-	46883	-	44160
	c. Life Science Chemicals	136689	141672	-	136689	-	120265
	d. Unallocable corporate assets	13788	14698	5	13788	5	18070
	Total segment assets	361757	368236	5	361757	5	337852
4	Segment liabilities						
	a. Speciality Chemicals	23720	29039	-	23720	-	33180
	b. Nutrition & Health Solutions	7792	7719	-	7792	-	7215
	c. Life Science Chemicals	63880	68065	-	63880	-	46601
	d. Unallocable corporate liabilities	39652	55800	17	39652	17	58562
	Total segment liabilities	135044	160623	17	135044	17	145558



Jubilant Ingrevia Limited

Note3: Additional disclosure as per Regulation 52 (4) and 54 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Consolidated)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30 September	30 June	30 September	30 September	30 September	31 March
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2021	2021	2020	2021	2020	2021##
1	Debt service coverage ratio (in times)# <i>Definition: EBITDA/(finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts)</i> {EBITDA: Profit before tax + depreciation and amortisation expense + finance costs + exceptional items}	12.97	8.60	-	8.00	-	5.60
2	Interest service coverage ratio (in times) <i>Definition: EBITDA/finance costs</i>	28.27	22.44	-	24.53	-	16.34
3	Bad debts to account receivable ratio (%)# <i>Definition: Bad debts/average of opening and closing trade receivables</i> {Bad debts: Impairment balance as per statements of profit and loss} {Accounts receivables: Trade receivables as per balance sheet}	0.08%	-	-	0.09%	-	0.17%
4	Debtors turnover (in times)# <i>Definition: Revenue from operations/average of opening and closing trade receivables</i>	2.07	2.17	-	4.45	-	1.31
5	Inventory turnover (in times)# <i>Definition: Cost of goods sold/average of opening and closing inventories</i>	0.91	0.81	-	1.89	-	0.55
6	Operating margin (%) <i>Definition: Operating profit/revenue from operations</i> {Operating profit: Operating Revenue - cost of goods sold - operating Expenses - depreciation and amortisation expense} {Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress} {Operating Expenses: Employee benefits expense + other expenses}	13.47%	21.83%	-	17.52%	-	12.00%
7	Net profit margin (%) <i>Definition: Net profit for the period/total income</i>	9.01%	14.62%	-	11.72%	-	7.92%
8	Paid-up debt capital (In ₹ Lakhs) <i>Definition: Secured Rated Listed Redeemable Non-Convertible Debentures (Gross of debt initiation cost)</i>	10000			10000		10000
9	Net worth (In ₹ Lakhs)	226713			226713		192294
10	Debt equity ratio (in times) <i>Definition: Net debts/net worth</i> {Net debts: Long term borrowings (including current maturities and gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances}	0.09			0.09		0.22
11	Current ratio (in times) <i>Definition: Current assets/current liabilities</i>	1.68			1.68		1.59
12	Long term debt to working capital (in times) <i>Definition: Long term debt/working capital</i> {Long term debt: Long term borrowings (including current maturities and gross of transaction costs)} {working capital: Current assets - current liabilities}	0.27			0.27		0.86
13	Current liability ratio (in times) <i>Definition: Current liabilities/total liabilities</i>	0.74			0.74		0.61
14	Total debts to total assets (in times) <i>Definition: Total debts/total assets</i> {Total debts: Long term borrowings (including current maturities and gross of transaction costs + short term borrowings)}	0.07			0.07		0.16
15	Fixed assets coverage ratio (in times) <i>Definition: Total assets secured by a first pari-passu charge / indebtedness secured by or agreed to be secured by first charge over fixed assets (i.e. aggregate external borrowing)</i>	10.63			10.63		4.26

not annualised

Figures for the year ended 31 March 2021 are not comparable as it represents only two months of operations of Life Science Ingredients business from 1 February 2021 to 31 March 2021 (refer note 10 for further details).



4. The Group has considered the possible effects that may result from the Covid-19 pandemic, on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions, the Group has, as at the date of approval of these consolidated financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the Group. On the basis of evaluation and current indicators of future economic conditions, the Group expects to recover the carrying amounts of these assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties associated with its nature and duration. The Group will continue to monitor any material changes to future economic conditions.
5. Pursuant to the Composite Scheme, the Life Science Ingredients business ("LSI business") of Jubilant Pharmova Limited got demerged into the Holding Company w.e.f. 1 February 2021, accordingly the consolidated financial results of the Group for quarter and year ended 31 March 2021 includes only two months of operations of LSI business from 1 February 2021 to 31 March 2021. Therefore, in order to present the actual scale of operation of the LSI business, the management has presented, in addition to, the consolidated financial results of the Group, the following financial information which has been derived/extracted from the discontinued operations disclosure in the financial results of the transferor company, Jubilant Pharmova Limited for respective periods presented, which has not been separately subjected to audit or review and has been presented as 'unaudited' supplementary information:

Particulars	(₹ in Lakhs)		
	Quarter Ended	Half Year Ended	Year Ended
	30 September	30 September	31 March
	(Unaudited)	(Unaudited)	(Unaudited)
	2020 (3 months)	2020 (6 months)	2021 (10 months)
i) Total revenue from operations	78354	152039	280698
ii) Other income	383	805	1220
iii) Total income	78737	152844	281918
iv) Total expenses	69538	136796	247825
v) Profit before tax	9199	16048	34093
vi) Tax expenses	1477	3064	7918
vii) Net profit for the period	7722	12984	26175

6. On 8 October 2021, the Holding Company has entered into Share Purchase, Subscription and Shareholder's Agreement with AMP Energy C&I Private Limited and AMP Energy Green Fifteen Private Limited for acquisition of 26.60% stake of AMP Energy Green Fifteen Private Limited for putting up the solar power plant with capacity of 15.5 MW for Captive Power Consumption.
7. During the quarter ended 30 September 2021, the Holding Company has granted 41867 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Holding Company.
8. During the quarter ended 30 September 2021, Jubilant Life Sciences International Pte. Limited, Singapore, a wholly owned subsidiary of the Holding Company has divested its entire 10% stake, consisting of 5,40,463 shares, held in Safe Foods Corporation on 21 September 2021 for a consideration of USD 18.2 million (~ 13421 Lakhs), pursuant to approval of the plan of merger between Safe Food Corporation and Packers Sanitation Services Inc. Limited.
9. The Secured Rated Listed Redeemable Non-Convertible Debentures (NCDs) aggregating to ₹10000 lakhs outstanding as at 30 September 2021 are secured by a first pari-passu charge created by way of mortgage on certain immovable assets and hypothecation on entire movable property, plant and equipment, both present and future, of the Company. On 6 May 2021, CRISIL Limited has assigned the rating of "CRISIL AA/ Stable" to the said NCDs. The asset cover thereof based on agreed methodology exceeds 100% of the outstanding principal amount of the said NCDs.

Details of due dates for payment of interest and repayment of principal of NCDs are as follows:

Particulars	Previous Due Date		Next Due Date	
	Principal	Interest	Principal	Interest
1000 – 7.90% Non - Convertible Debentures of ₹ 10 lakhs each	-	2 June 2021*	2 June 2023	2 June 2022

*Interest due on 2 June 2021 has been paid on the due date

10. The figures for the quarter ended 30 September 2021 and half year ended 30 September 2021 are not comparable with previous periods since the figures for quarter and half year ended 30 September 2020 is without the results of LSI business and the figures for the year ended 31 March 2021 include results of demerged LSI business from Jubilant Pharmova Limited for two months, from the effective date of demerger i.e., 1 February 2021 till 31 March 2021. Further, figures for quarter and half year ended 30 September 2020 have not been subjected to audit or review by the Statutory Auditors as they are for the period before listing of the Holding Company i.e. 19 March 2021.
11. Previous period figures have been regrouped /reclassified to conform to the current period's classification.
12. The above consolidated unaudited financial results were subjected to limited review by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 19 October 2021. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on consolidated financial results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.



Place : Noida
Date : 19 October 2021

For Jubilant Ingrevia Limited

RAJESH KUMAR
SRIVASTAVA

Digitally signed by RAJESH
KUMAR SRIVASTAVA
Date: 2021.10.19 13:46:07
+05'30'

Rajesh Kumar Srivastava
CEO & Managing Director